Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.

BeOne aims to be a next-generation oncology innovator by broadening its drug and pipeline portfolio to various solid tumors in addition to blood cancers. As such, it been actively investing to build ...

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal ...

F our trials presented at the recent American Society of Clinical Oncology (ASCO) meeting showed promise of new drug ...

A trio of analysts raised their price targets on the pharmaceutical sector mainstay. This came a day after it published second-quarter results. 10 stocks we like better than AbbVie › A ...

In the last three months, 4 analysts have published ratings on AbbVie ABBV, offering a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their ...

One of the letters was sent to AbbVie CEO Rob Michael. In it, Trump wrote, "Right now, brand name drug prices in the United States are up to three times higher on average than elsewhere for the ...

AbbVie expects full-year earnings in the range of $11.88 to $12.08 per share. AbbVie shares have risen 6.5% since the beginning of the year, while the S&P’s 500 index has risen 8%.

AbbVie is in talks to acquire mental health therapeutics company Gilgamesh Pharmaceuticals in a deal highlighting growing takeover interest in the sector, according to people familiar with the matter.